Fibrinspecific liposomes as a potential method of delivery of the thrombolytic preparation streptokinase
- PMID: 34816379
- DOI: 10.1007/s11239-021-02614-0
Fibrinspecific liposomes as a potential method of delivery of the thrombolytic preparation streptokinase
Abstract
The use of streptokinase (SK) in the clinic is limited by the lack of fibrin-specificity and the short half-life of the drug. We have developed a new dosage form of streptokinase (immunoliposome), which consists of "free" native streptokinase and "bound" encapsulated in liposomes conjugated through carboxylated dextran with fibrin-specific monoclonal antibodies FnI-3C (IgG2 class), in a ratio of 60 and 40%, respectively, and studied their physicochemical properties, pharmacokinetic parameters, and the ability of fibrin-specific liposomes with SK for targeted delivery to fibrin in an in vivo experiment. The obtained immunoliposomes had a hydrodynamic diameter of ~ 140 nm, a zeta potential of - 19.6 mV, and entrapment efficiency of 14.1%. Fluorescent labels bound to immunoliposomes with streptokinase selectively accumulated in model rat vein thrombi at sites containing fibrin in 30 min after injection. Studies of pharmacokinetic parameters showed that the administration of immunoliposomes with streptokinase to rats was accompanied by an increase in the half-life from 1.8 to 24.1 min, the time to reach the maximum concentration from 15 to 30 min, and a decrease in the elimination constant by about 13 times compared with the native streptokinase preparation. Further studies are needed to evaluate the thrombolytic efficacy a new dosage form of streptokinase in experiment in vivo.
Keywords: Drug delivery system; Immunoliposomes; Liposomes; Pharmacokinetics; Streptokinase.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Zhang H (2017) Thin-film hydration followed by extrusion method for liposome preparation. In: D’Souza G (ed) Liposomes. Methods in molecular biology, vol 1522. Humana Press, New York
-
- Koudelka S, Mikulik R, Mašek J, Raška M, Turánek Knotigová P, Miller AD, Turánek J (2016) Liposomal nanocarriers for plasminogen activators. J Control Release 227:45–57. https://doi.org/10.1016/j.jconrel.2016.02.019 - DOI - PubMed
-
- Sen Gupta A (2016) Cardiovascular nanomedicine: materials and technologies. In: Lu ZR, Sakuma S (eds) Nanomaterials in pharmacology. Methods in pharmacology and toxicology. Humana Press, New York, pp 251–277
-
- Ramezanpour M, Leung SS, Delgado-Magnero KH et al (2016) Computational and experimental approaches for investigating nanoparticle-based drug delivery systems. Biochim Biophys Acta 1858(7 Pt B):1688–1709. https://doi.org/10.1016/j.bbamem.2016.02.028 - DOI - PubMed
-
- Kesov PG, Reitblat OM, Safiullina ZM, Shalaev SV (2014) Evolyutsiya tromboliticheskoi terapii v lechenii infarkta miokarda [evolution of thrombolytic therapy in the treatment of myocardial infarction]. Ratsional’naya farmakoterapiya v kardiologii 10(5):554–558 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources